Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term external-beam radiotherapy. Found 14 abstracts

Buyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG. Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. Journal of Clinical Oncology. 2012 May;30(15):1857-63.   PMCID: not NIH funded
Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan;11(1):6-19.   PMCID: not NIH funded
Lubbe W, Cohen R, Sharma N, Ruth K, Peters R, Li JS, Buyyounouski M, Kutikov A, Chen D, Uzzo R, Horwitz E. Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy. Brachytherapy. 2012 May;11(3):209-13.
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Sep;10(9):1081-7.   PMCID: Not NIH Funded
Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Dec;78(5):1314-22.   PMCID: PMCID: PMC2920356 [Available on 2011/12/1]
Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Jul;65(4):965-74.
Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2005 Dec;63(5):1455-62.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?. International Journal of Radiation Oncology Biology Physics. 2005 Mar 15;61(4):1003-10.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. International Journal of Radiation Oncology Biology Physics. 2005 Mar;61(3):695-701.
Konski A, Feigenberg S, Chow E. Palliative radiation therapy. Seminars in Oncology. 2005 Apr;32(2):156-64.
Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: Can one size fit all?. International Journal of Radiation Oncology Biology Physics. 2005 Feb;61(2):409-14.
Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M, Gore EM, Tepper JE. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: An astro outcomes initiative. International Journal of Radiation Oncology Biology Physics. 2005 May;62(1):3-19.
Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics. 2002 Aug;53(5):1097-105.
Movsas B, Hanlon AL, Teshima T, Hanks GE. Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer. 1997 Sep 15;80(6):1093-102.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term external-beam radiotherapy

external-beam radiotherapy radiotherapy radical prostatectomy radiation-therapy adenocarcinoma prostate cancer follow-up phase-iii trial neoadjuvant cancer carcinoma seed implantation prostate-specific antigen androgen deprivation therapy Radiation therapy quality-of-life antigen free survival prostatic neoplasms irradiation Prostate cancer escalation conformal radiation-therapy american society conformal radiotherapy risk grade prospective randomized-trial partitioning analysis rpa Safety multiinstitutional analysis body-mass index dose-rate brachytherapy prostate neoplasms Androgen deprivation therapy definitive radiotherapy painful bone metastases therapy Brachytherapy 1980 aryulu kkn-international journal of radiation oncology biology physics-v6-p1261 iii randomized trial Nuclear Medicine & Medical Imaging Radiology systematic review radiology therapeutic radiology Interstitial malignant airway-obstruction dose-volume histograms Dosimetry randomized trial biochemical recurrence Standard locally advanced-carcinoma biochemical failure modulated radiation-therapy survival replacement therapy Radiotherapy adjuvant therapy deprivation less-than-or-equal-to-10 prostate specific Clinical trials adjuvant androgen ablation retention prognosis pathological stage ASTRO failure definition prostate carcinoma competing Quality assurance biopsy cores definitions pelvic irradiation postimplant randomized-trial brachytherapy Brachytherapy Prostate cancer-Implant-Small-volume prostate size acute urinary predict pathological stage outcomes three-dimensional conformal radiotherapy Serum testosterone androgen deprivation recursive partitioning analysis androgen suppression PSA failure PSA disease-free survival hypogonadal men three-dimensional radiotherapy randomized prostate dosimetric analysis Oncology abiraterone acetate gleason score multi-institutional analysis antigen doubling time volume histogram analysis treatment failure dose-response high risk stage prognostic factor radiation therapy i-125 brachytherapy morbidity surrogate end-point pathological Guideline pubic arch interference radiation low-dose rate symptomatic osseous metastases photons Prognostic factors antigen bounce dose escalation acute toxicity trial interstitial-brachytherapy spinal-cord compression rectal toxicity level psa mortality local-control consensus definition invasive bladder-cancer androgen volume dose cell lung-cancer
Last updated on Thursday, August 06, 2020